Less Ads, More Data, More Tools Register for FREE

RTW Biotech invests in cell and gene therapy company Obsidian

Fri, 05th Apr 2024 12:14

(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has backed cell and gene therapy-focused biotech Obsidian Therapeutics Inc.

The investment company, focused on assets in the life sciences sector, said it partook in an Obsidian funding round which raised USD160.5 million.

Obsidian, a biotechnology company specialising in cell and gene therapy, will use the proceeds for the development and ongoing trials of OBX-115.

The therapy is a next-generation tumour-infiltrating lymphocyte for patients with metastatic melanoma and non-small cell lung cancer.

RTW shares were down 0.5% to 103.50 pence each in London on Friday afternoon.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Related Shares

More News

13 Jun 2024 16:41

TRADING UPDATES: Christie trading improved, maintains expectations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

11 Jun 2024 10:54

RTW Biotech portfolio company to sell subsidiary for USD1.25 billion

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted the proposed sale of a subsidiary belonging to its portfolio company Numab Therapeuti...

15 May 2024 21:43

TRADING UPDATES: Future Metals celebrates state government grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

2 Apr 2024 11:15

EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...